Several trials were failed to found a significant association between PI3K inhibitors and PIK3CA-mutant breast cancer[26, 46], which brings into question whether PIK3CA mutation are targetable in the clinic setting[47]. This evidence concerns the gene PIK3CA and breast cancer.